Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy. The gene discussed is TTR; the disease is Familial transthyretin-related amyloidosis.